MedTrace Logo

Treatment of Childhood Acute Lymphoblastic Leukemia

NCT00165087 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 491

Last updated 2007-12-28

No results posted yet for this study

Summary

The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia therapy, to attain long-term control of the disease and to hopefully eradicate it.

Conditions

Interventions

DRUG

asparaginase (E. Coli)

DRUG

asparaginase (Erwina)

DRUG

dexrazoxane

DRUG

doxorubicin

PROCEDURE

cranial radiation (once daily fractionation)

PROCEDURE

cranial radiation (twice-daily fractionation)

PROCEDURE

Intrathecal chemotherapy without radiation

Sponsors & Collaborators

Principal Investigators

  • Stephen E. Sallan, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-01-31
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • United States
  • Canada
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165087 on ClinicalTrials.gov